Heron Therapeutics appoints Ira Duarte as CFO effective June 16, 2023

HERON THERAPEUTICS, INC. /DE/

Ira Duarte named CFO; previously CFO of Veloxis Pharmaceuticals and held finance roles at BioDelivery Sciences, Chiesi USA, and Ernst & Young.
Compensation includes $500K base salary, $250K target bonus (pro-rated for 2023), and inducement award of options for 800K shares, 50K RSUs, and performance options for up to 500K shares.
Inducement award granted outside 2007 Plan with four-year vesting for options and RSUs; performance options vest based on stock price goals.
Duarte also holds a board seat at TerrAscend Corp. since December 2022 and is a CPA with a BS in Accounting from Florida Atlantic University.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Ira Duarte

Chief Financial Officer

HRTX · HERON THERAPEUTICS, INC. /DE/

Effective: 2023-06-16
Filed: June 23, 2023, 7:59 PM ET

appointed Ira Duarte as Chief Financial Officer, effective June 16, 2023

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ira Duarte was appointed as Chief Financial Officer at HERON THERAPEUTICS, INC. /DE/.

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

appointed Ira Duarte as Chief Financial Officer, effective June 16, 2023

View on SEC.gov

HERON THERAPEUTICS, INC. /DE/ filing history →

Source: SEC EDGAR

accession 0000950170-23-029646

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.